Analysis of daratumumab for newly diagnosed systemic light chain amyloidosis, October 2025
Page last updated: 20 March 2026
Drug utilisation sub-committee (DUSC)
October 2025
Abstract
Purpose
To review the utilisation of daratumumab for newly diagnosed systemic light-chain AL amyloidosis as requested by DUSC at its June 2025 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Daratumumab was listed for the treatment of newly diagnosed systemic light chain amyloidosis on 1 January 2023.
Data Source / methodology
Data extracted from the PBS and Date of Death database maintained by Department of Health, Disability and Ageing, processed by Services Australia were used for the analyses.
Key Findings
- In 2023, 294 patients were supplied 3,270 prescriptions for the treatment of AL amyloidosis.
- In 2024, 443 patients were supplied 4,881 prescriptions for the treatment of AL amyloidosis.
- The median age of patients initiating treatment with daratumumab for the treatment of AL amyloidosis was 70 years.
- Utilisation was different from estimated with a greater number of patients initiating than estimated, and a lower number of prescriptions supplied than estimated
